Alle Storys
Folgen
Keine Story von Marinomed Biotech AG mehr verpassen.

Marinomed Biotech AG

EANS-Voting Rights: Marinomed Biotech AG
Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

--------------------------------------------------------------------------------
  Notification of voting rights transmitted by euro adhoc with the aim of a
  Europe-wide distribution. The issuer is responsible for the content of this
  announcement.
--------------------------------------------------------------------------------


Overview

Notification made after deadline
Caution: In case of violations of major holdings notification rules, please pay
attention to Section 137 BörseG 2018 (Suspension of voting rights)

1. Issuer: Marinomed Biotech AG

2. Reason for the notification:
Acquisition or disposal of voting rights

3. Person subject to notification obligation
Acting in concert agreement (Sec. 133 No. 1 BörseG 2018)

Name: Conseq Invest Akcie Nové Evropy
City: Dublin
Country: Ireland

Name: Conseq globální akciový úcastnický fond
City: Prague
Country: Czech Republic

4. Name of shareholder(s):

5. Date on which the threshold was crossed or reached: 27.1.2020

6. Total positions

 _____________________________________________________________________________
|             |               |  % of voting  |               |               |
|             |  % of voting  |rights through |               |Total number of|
|             |rights attached|financial/other|Total of both  | voting rights |
|             |to shares (7.A)| instruments   |in % (7.A +    |   of issuer   |
|_____________|_______________|(7.B.1_+_7.B.2)|7.B)___________|_______________|
|  Resulting  |               |               |               |               |
|situation on |               |               |               |               |
| the date on |               |               |               |               |
|    which    |    4.08 %     |    0.00 %     |         4.08 %|1,469,770      |
|  threshold  |               |               |               |               |
|was crossed /|               |               |               |               |
|___reached___|_______________|_______________|_______________|_______________|
|Position of  |               |               |               |               |
|previous     |               |               |               |               |
|notification |               |               |               |               |
|(if          |               |               |               |               |
|applicable)__|_______________|_______________|_______________|_______________|



Details
7. Notified details of the resulting situation:

 ______________________________________________________________________________
|A:_Voting_rights_attached_to_shares___________________________________________|
|            |Number_of_voting_rights_________|%_of_voting_rights______________|
|            |    Direct     |Indirect (Sec   |    Direct     |Indirect (Sec   |
|ISIN Code   |(Sec 130 BörseG|133 BörseG      |(Sec 130 BörseG|133 BörseG      |
|____________|_____2018)_____|_____2018)______|_____2018)_____|_____2018)______|
|AT0000831706|_______________|__________60,000|_______________|__________4.08_%|
|SUBTOTAL_A__|__________________________60,000|__________________________4.08_%|




 __________________________________________________________________________
|B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1     |
|BörseG_2018_______________________________________________________________|
|          |               |                 |Number of voting |           |
|          |               |                 | rights that may |           |
|Type of   |Expiration Date|  Exercise Period| be acquired if  |% of voting|
|instrument|               |                 |the instrument is|rights     |
|__________|_______________|_________________|____exercised____|___________|
|__________|_______________|_________________|_________________|___________|
|__________________________|_____SUBTOTAL_B.1|_________________|___________|




 ________________________________________________________________________
|B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2   |
|BörseG_2018_____________________________________________________________|
|          |Expiration|Exercise|Physical / Cash|Number of    |% of voting|
|Type of   |Date      |Period  |Settlement     |voting rights|rights     |
|instrument|__________|________|_______________|_____________|___________|
|__________|__________|________|_______________|_____________|___________|
|______________________________|_SUBTOTAL_B.2__|_____________|___________|



8. Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the
financial/other instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

 ______________________________________________________________________________
|            |            |            |            | Financial/ |             |
|            |            |  Directly  |Shares held |   other    |Total of both|
|    No.     |    Name    | controlled |directly (%)|instruments |     (%)     |
|            |            |   by No.   |            |    held    |             |
|____________|____________|____________|____________|directly_(%)|_____________|
|___________1|__Jan_Vedral|____________|______0.00_%|______0.00_%|_______0.00_%|
|            |      Conseq|            |            |            |             |
|           2|  Investment|           1|      0.00 %|      0.00 %|       0.00 %|
|            | Management,|            |            |            |             |
|____________|________a.s.|____________|____________|____________|_____________|
|            |      Conseq|            |            |            |             |
|           3|    Penzijní|           2|      0.00 %|      0.00 %|       0.00 %|
|            | spole¿nost,|            |            |            |             |
|____________|________a.s.|____________|____________|____________|_____________|
|            |      Conseq|            |            |            |             |
|            |    globální|            |            |            |             |
|           4|     akciový|           3|      2.33 %|      0.00 %|       2.33 %|
|            |  úcastnický|            |            |            |             |
|____________|________fond|____________|____________|____________|_____________|
|           5|      Conseq|            |      0.00 %|      0.00 %|       0.00 %|
|____________|__Invest_Plc|____________|____________|____________|_____________|
|            |      Conseq|            |            |            |             |
|           6|Invest Akcie|           5|      1.75 %|      0.00 %|       1.75 %|
|____________|_Nové_Evropy|____________|____________|____________|_____________|


9. In case of proxy voting
Date of general meeting: -
Voting rights after general meeting: - is equivalent to - voting rights.

10. Other comments:
Shares are held by two investment funds managed by investment companies as
stated above acting in concert.



Further inquiry note:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail:  eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail:  r.mayrl@metrum.at
http://www.metrum.at


end of announcement                         euro adhoc
--------------------------------------------------------------------------------
issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:          office@marinomed.com
WWW:       www.marinomed.com
ISIN:         ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language:     English

Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell

Weitere Storys: Marinomed Biotech AG
Weitere Storys: Marinomed Biotech AG